Literature DB >> 10508482

Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells.

H M Sowter1, A N Corps, S K Smith.   

Abstract

Hepatocyte growth factor (HGF) is a pleiotropic growth factor implicated in the growth and spread of some epithelial tumours. The epithelial cells of a proportion of ovarian tumours, and some ovarian carcinoma cell lines, express high levels of the HGF receptor, c-Met. In this study, we show that ovarian ascitic fluid as well as benign and malignant ovarian cyst fluids contain significant levels of HGF. Ovarian cyst and ascitic fluid stimulated the migration of the ovarian carcinoma cell line, SK-OV-3, and this was greatly reduced by the addition of an HGF-neutralising antibody. Non-malignant peritoneal fluid contained low levels of HGF, and did not stimulate migration of the SK-OV-3 cells. Our results show that HGF is present in benign and malignant ovarian cyst and ascitic fluid, and that HGF in ovarian tumour fluid may be a major inducer of ovarian carcinoma cell migration. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508482     DOI: 10.1002/(sici)1097-0215(19991112)83:4<476::aid-ijc7>3.0.co;2-v

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.

Authors:  Sylvia Herter; Derek E Piper; Wade Aaron; Timothy Gabriele; Gene Cutler; Ping Cao; Ami S Bhatt; Youngchool Choe; Charles S Craik; Nigel Walker; David Meininger; Timothy Hoey; Richard J Austin
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

2.  Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance.

Authors:  Enze Li; Zheng Hu; Yi Sun; Qi Zhou; Bin Yang; Zhiguo Zhang; Wenwu Cao
Journal:  Tumour Biol       Date:  2015-12-23

Review 3.  Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer.

Authors:  Youngjoo Kwon; Andrew K Godwin
Journal:  Reprod Sci       Date:  2016-09-27       Impact factor: 3.060

4.  SF/HGF-c-Met autocrine and paracrine promote metastasis of hepatocellular carcinoma.

Authors:  Q Xie; K D Liu; M Y Hu; K Zhou
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

5.  c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.

Authors:  Maggie K S Tang; Hong Y Zhou; Judy W P Yam; Alice S T Wong
Journal:  Neoplasia       Date:  2010-02       Impact factor: 5.715

Review 6.  The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.

Authors:  Kim Moran-Jones
Journal:  Mol Diagn Ther       Date:  2016-06       Impact factor: 4.074

7.  A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Authors:  Lainie P Martin; Michael Sill; Mark S Shahin; Matthew Powell; Paul DiSilvestro; Lisa M Landrum; Stephanie L Gaillard; Michael J Goodheart; James Hoffman; Russell J Schilder
Journal:  Gynecol Oncol       Date:  2013-12-18       Impact factor: 5.482

Review 8.  EMT-Inducing Molecular Factors in Gynecological Cancers.

Authors:  Loredana Campo; Catherine Zhang; Eun-Kyoung Breuer
Journal:  Biomed Res Int       Date:  2015-08-19       Impact factor: 3.411

Review 9.  Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.

Authors:  Nuzhat Ahmed; Kaye L Stenvers
Journal:  Front Oncol       Date:  2013-09-25       Impact factor: 6.244

10.  MET/HGF Signaling Pathway in Ovarian Carcinoma: Clinical Implications and Future Direction.

Authors:  Paulette Mhawech-Fauceglia; Michelle Afkhami; Tanja Pejovic
Journal:  Patholog Res Int       Date:  2012-12-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.